We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...

PBD-Dimer Payloads for Antibody Drug Conjugates


PBD Report Visual

A robust Approach to cGMP production

From the 1960s when monomeric pyrrolobenzodiazepines (PBDs) such as anthramycin were isolated and characterized, to the dramatic increase of potency induced by dimerization in the 2000s, PBD dimers have evolved as one of the leading classes of antibody drug conjugate (ADC) payloads. Currently, 17 ADCs are in clinical trials involving PBD-dimers. Four different PBD-dimer ADC payloads are in clinical trials: Talirine (SGD-1910) from Seattle Genetics; Tesirine (SG3249) from Spirogen, MedImmune, ADC Therapeutics, and Abbvie; and DGN462 and DGN549 from Immunogen.

With the most advanced PBD-ADC program, Abbvie- StemCentrx’ Rovalpituzumab-tesirine (Rova-T) closing to commercial launch, this technical report summarizes the production challenges and solutions presented by the PBD-dimer platform.

What you will learn :

> The Specific Challenges of PBD Synthesis and Purification
> Conjugation of PBD-Dimer Payloads
> Drug-to-Antibody Ratio (DAR) & Conjugation Process   
> And much more!

Thank you for your submission ! You can now download your file by clicking on the button below:

Back to resources